DigestRedComo funciona
Red
/
Empresas
Bi
No verificado

Biogen Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

53 Comunicados de prensa

Ver todos los comunicados de prensa
12/01/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
22/12/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
05/12/2025
Biotecnología
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
24/11/2025
Biotecnología
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
14/11/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Biogen Completes Acquisition of Alcyone Therapeutics
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnología
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
24/10/2025
Biotecnología
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
22/10/2025
Biotecnología
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0